This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
1. Approach to FUO
This module covers the initial evaluation of prolonged fever, including exposure history, baseline tests, infectious and noninfectious causes, and indications for imaging or biopsy.
The fellow section covers culture-negative endocarditis, PET/CT, tissue sampling, molecular testing, and inflammatory disorders.
The exposure table can also be used during a consult.
2. Definition and patient population
New fever in the hospitalized patient · Opportunistic infection evaluation in HIV
Classic FUO is prolonged documented fever, conventionally at least 38.3°C on several occasions over at least three weeks, without an explanation after an appropriate minimum evaluation in an immunocompetent adult. The 2024 Delphi consensus emphasizes the tests completed over the number of inpatient days. The three-week convention helps define a teaching and research population. Urgent evaluation depends on the presentation from the first encounter.
| Presentation | How to approach it |
|---|---|
| New fever over hours to days | The acute syndrome and its severity guide evaluation. Negative initial cultures alone are insufficient for FUO classification. |
| New hospital or ICU fever | Recent procedures, devices, aspiration, thrombosis, transfusion, drugs, and new infection help distinguish causes of hospital-acquired fever. |
| Neutropenia, transplant, substantial immunosuppression, or advanced HIV | Immune status and likely opportunistic infections determine urgency and testing. These populations need separate pathways from classic FUO. |
| Inflammation of unknown origin | The 2024 panel defines this group as immunocompetent patients with unexplained inflammatory-marker elevation for more than three weeks after a minimum evaluation and without fever above 38.3°C. Causes overlap with FUO. Elevated CRP alone does not establish infection. |
Recorded temperatures, measurement method, antipyretic use, and timing help characterize the fever. Examination during an episode may reveal transient findings.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · SCCM/IDSA guideline on new fever in adult ICU patients. 2023.
3. When treatment cannot wait
| Finding | Why evaluation and treatment are urgent |
|---|---|
| Possible septic shock, probable or definite sepsis, or rapidly worsening organ dysfunction with suspected infection | The Surviving Sepsis Campaign calls for immediate resuscitation and antimicrobials in possible septic shock or probable or definite sepsis. Blood cultures are most useful before antibiotics when they can be collected without delay. An infection that needs drainage or another procedure calls for early source control. |
| Febrile neutropenia | Febrile neutropenia requires prompt empiric treatment under a host-specific pathway. |
| Meningismus, encephalopathy, new neurologic deficit, or back pain with neurologic signs | A possible CNS infection or spinal emergency needs urgent evaluation and indicated empiric treatment. A delayed or unsafe lumbar puncture must not postpone necessary therapy. |
| New visual symptoms with a convincing giant cell arteritis syndrome | Threatened vision requires urgent specialist assessment and glucocorticoid treatment. Vascular imaging or biopsy can support the diagnosis and must not delay vision-saving treatment. |
| Cytopenias, hepatitis, coagulopathy, rising ferritin, and deterioration | This pattern raises concern for HLH/MAS and warrants urgent multidisciplinary assessment. Infection and malignancy remain possible triggers or alternatives. |
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · Surviving Sepsis Campaign adult guidelines. 2026. · IDSA febrile neutropenia guideline. 2010 update, published 2011. · WHO meningitis guidelines. 2025. · Dejaco et al. EULAR imaging recommendations for large vessel vasculitis, 2023 update. Published 2024. · Shakoory et al. EULAR/ACR points to consider in suspected HLH/MAS. Published 2023.
Workup by stage
This sequence is for a stable, immunocompetent adult with prolonged unexplained fever. History, examination, and earlier results may move a test to an earlier stage or make it unnecessary. A focal finding should be evaluated when identified.
| Stage | Evaluation | When to change the sequence |
|---|---|---|
| First assessment | The initial assessment establishes the fever timeline, immune status, medications, exposures, prior tests, and examination findings. Hypotension or organ injury changes the urgency. | Shock, febrile neutropenia, suspected meningitis, and threatened vision from giant cell arteritis are indications for urgent evaluation and treatment. |
| Initial workup | The Delphi minimum includes CBC with differential, a metabolic panel with liver tests and calcium, ESR/CRP, ferritin, TSH, ANA, ANCA, and RF. It also includes three blood-culture sets, urinalysis with microscopy, HIV screening, and an IGRA or TST. The panel preferred CT chest, abdomen, and pelvis when available. Chest radiography plus abdominal ultrasound is an alternative. | Completed tests and specimen timing determine whether repetition adds value. Blood cultures have better yield before antibiotics when collection is feasible without delay. Suspected active TB calls for site-specific specimens regardless of IGRA/TST results. |
| Additional tests based on findings | Echocardiography for suspected endocarditis; MRI for focal spinal symptoms; exposure-specific serology, PCR, or fungal testing; selected viral studies; CSF studies for a neurologic presentation; organ-directed rheumatologic or hematologic evaluation. | These tests may belong in the initial evaluation. Examples include TEE with a prosthetic valve and suspected endocarditis, malaria smears after relevant travel, or MRI for back pain with neurologic findings. |
| If the initial evaluation is unrevealing | A repeat history, examination, and medication timeline can uncover new clues. Once the patient meets FUO criteria, the Delphi panel identifies FDG PET/CT as an important early test when available, particularly if no diagnostic clue has emerged. A suitable node, skin lesion, or imaging abnormality can provide tissue for diagnosis. | An accessible suspicious lesion can be biopsied earlier. Progressive cytopenias or an abnormal smear may warrant marrow evaluation. PET uptake alone does not distinguish infection, inflammation, and malignancy. |
| If no diagnosis is found | The completed workup and pending results guide follow-up. Selected molecular tests may help when a specific infectious concern remains. Stable patients may be followed with repeat examination and laboratory testing as clinically indicated. | New focal symptoms, falling blood counts, or renal or liver injury require reassessment. In a stable patient, the Delphi consensus reserves nonspecific antibiotic or glucocorticoid trials for selected cases after diagnostic options have been exhausted. |
These stages illustrate how the workup can change as clues emerge. Exposure-based tests depend on the patient’s history, timing, and syndrome.
Sources FUO consensus, OFID 2024 · Contemporary ambulatory FUO approach, CID 2026 · EANM PET/CT consensus, 2024
4. History and examination
Ask where the patient has lived and traveled, what they did there, and when. Clarify animal contact and work or recreational exposures. Ask whether others became ill. Take the sexual and substance-use history privately.
Social and exposure history
| Ask the patient | What it raises | Testing when the syndrome fits |
|---|---|---|
| Where have you lived and traveled, including earlier in life? When did you return? Rural or urban? What did you do there? | Malaria, TB, endemic fungi, and geographically restricted infections. Country alone is insufficient. | Possible malaria warrants urgent thick and thin smears. CDC advises repeating initially negative smears every 12–24 hours for a total of three sets when suspicion remains. Itinerary and syndrome guide additional testing. |
| Any TB contacts? Prior TB treatment? Time in shelters, correctional facilities, or other crowded settings? | Pulmonary or extrapulmonary TB. Remote exposure may matter. | IGRA/TST is baseline infection testing. Suspected active disease requires site-specific imaging and microbiology; a negative IGRA does not exclude it. |
| Do you handle cattle, sheep, goats, or animal placentas? Help with births? Work in veterinary care, farming, meat processing, or a laboratory? | Q fever and brucellosis, especially with hepatitis, endocarditis, or persistent systemic illness. | Coxiella serology, with PCR useful early in acute illness; Brucella cultures/serology with laboratory notification. Exposure alone does not establish either diagnosis. |
| Raw milk or unpasteurized cheese, including products brought from abroad? Wild-hog hunting or butchering? Veterinary vaccine needle sticks? | Brucellosis; route helps identify species and assay limitations. | When brucellosis is suspected, advance laboratory notification protects staff handling cultures. Routine serology cannot detect B. canis or RB51 infection, so exposure history and discussion with microbiology or public health can guide testing. |
| Cats or kittens? Scratches or flea infestation? Body lice? Access to showers and clean clothing? | B. henselae with adenopathy or hepatosplenic disease; B. quintana with lice exposure and culture-negative endocarditis. | Bartonella serology and selected PCR when indicated. Persistent antibodies and cross-reactivity complicate interpretation. |
| Ticks, hiking, gardening, hunting, brush clearing, or camping? Where and when? Any skin ulcer or enlarged node? | Ehrlichiosis and other tickborne infections; tularemia with compatible ulcer/nodal or pulmonary disease. Many present acutely rather than as classic FUO. | Ehrlichia blood PCR early; paired serology when appropriate. Tularemia serology/PCR or culture with laboratory warning. Treatment of a convincing acute rickettsial illness is time-sensitive even while results are pending. See acute tick-borne illness testing and treatment and regional exposure maps. |
| Caves, bat or bird droppings, demolition, chicken coops, soil disturbance, or dusty travel in the Southwest? | Histoplasmosis or other endemic mycoses, depending on location, host, and organ involvement. | Histoplasma urine/serum antigen for compatible illness; add antibody or tissue testing as indicated. Histoplasma and Blastomyces antigen cross-reactivity limits species attribution. |
| Floodwater, freshwater swimming, rodent infestation, sewage, or animal urine exposure? | Leptospirosis, especially with renal injury, hepatitis, or meningitis. | PCR and serology selected by illness timing and available specimen. Exposure without a compatible syndrome is insufficient. |
| New sexual partners or recent condomless exposure? Injected drugs, shared equipment, or nonmedical injections? | Acute HIV and other exposure-associated infections; injection-related bacteremia/endocarditis. | HIV Ag/Ab, adding RNA if acute HIV remains plausible despite negative/indeterminate screening. STI/hepatitis testing by exposure and syndrome; cultures and echo for suspected endocarditis. |
| What medicines, supplements, infusions, and intermittent drugs have you taken? Which started before fever, and which were added afterward? | Drug fever or a systemic drug reaction. Recently added antibiotics may perpetuate fever. | Review dates, rash, eosinophils, renal/liver injury. Stopping a suspected drug can help clarify the cause when discontinuation is safe. Organ injury raises concern for a systemic drug reaction and needs further evaluation. |
| Any operations, dental infection, implanted valve/device, vascular graft, orthopedic hardware, or recent procedure? | Endocarditis, device infection, or a deep postoperative focus. | Cultures and targeted echo/imaging. Hardware is a risk modifier; it does not prove the source. |
| Any steroids, biologics, cancer therapy, transplant, splenectomy, or immune disorder? | Changes both the differential and urgency. Substantial immunosuppression falls outside the classic immunocompetent FUO pathway. | The actual agent, dose, timing, prophylaxis, and immune recovery help determine the appropriate host-specific evaluation. |
History and examination beyond exposures
Ask about new headache, jaw fatigue or visual symptoms; back or focal bone pain; joint swelling or morning stiffness; transient rash; oral ulcers; pleuritic pain; diarrhea or blood in stool; weight loss; and symptom-free intervals. Examine the mouth, skin, nails, nodes, heart, abdomen/spleen, spine, joints, wounds, and device sites. Repeat the examination when new symptoms emerge.
Sources CDC Q fever testing · CDC brucellosis overview · CDC ehrlichiosis testing · CDC tularemia testing · CDC leptospirosis overview · CDC histoplasmosis testing · CDC Bartonella quintana overview · CDC malaria diagnosis · CDC HIV testing guidance
5. Differential diagnosis
| Category | Prioritize when the clinical pattern fits | Evaluation |
|---|---|---|
| Infection | Endocarditis or vascular infection, occult abscess, vertebral infection, extrapulmonary TB, exposure-associated zoonoses, acute HIV, and endemic fungi in the appropriate host | Cultures are most useful before antibiotics when feasible. Clinical findings and exposures guide imaging, echocardiography, tissue sampling, and organism-specific tests. |
| Noninfectious inflammation | Giant cell or other vasculitis, Still's disease, connective-tissue disease, sarcoidosis, inflammatory bowel disease | Look for vascular, articular, skin, renal, pulmonary, and GI manifestations. Interpret serology with the examination and organ findings. |
| Malignancy | Lymphoma and other hematologic disease, selected solid tumors | Review blood counts and smear; image and obtain an appropriate node or other lesion for pathology. |
| Other causes | Drug fever, venous thromboembolism, thyroiditis, tissue injury, and less often temperature measurement problems | Reconstruct medication chronology, test the suspected mechanism, and avoid unsupported labels. |
| Undiagnosed illness | A legitimate outcome after adequate evaluation in a clinically stable patient | A follow-up plan allows the workup to continue as findings emerge. Stable classic FUO generally does not warrant an empiric antibiotic trial. |
Consider histoplasmosis and tickborne infection in Missouri when the exposure and presentation fit. Include remote residence and travel in the history.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025.
Noninfectious causes
| Pattern | Consider | Next step |
|---|---|---|
| Older adult, new headache/jaw symptoms, visual change, or inflammatory shoulder/hip stiffness | Giant cell arteritis/PMR spectrum | Urgent assessment for visual symptoms; directed vascular imaging or biopsy. |
| Fever with rash, arthritis, serositis, renal or pulmonary findings | Connective-tissue disease or vasculitis | Organ-directed evaluation, urinalysis, and selected serology; involve rheumatology. |
| Spiking fever, transient rash, inflammatory arthritis, neutrophilia | Still’s disease | Assess infection and malignancy; ferritin supports the pattern but is not diagnostic. |
| Nodes, weight loss, organomegaly, or abnormal blood counts | Lymphoma/hematologic disease | Obtain suitable tissue; preserve architecture and coordinate flow cytometry. |
| New medicine, rash, eosinophilia, or renal/liver injury | Drug fever or systemic drug reaction | Medication chronology and evidence of organ involvement help distinguish isolated drug fever from a systemic reaction. The suspected drug can be withdrawn if it is safe to do so. |
| Painful thyroid or compatible thyroid symptoms | Thyroiditis | TSH and free T4, with directed thyroid evaluation. |
| Unilateral swelling, pleuritic pain, hypoxemia, or thrombosis risk | Venous thromboembolism | Use syndrome-appropriate diagnostic testing rather than screening all FUO patients. |
Sources Contemporary ambulatory FUO approach, CID 2026 · EULAR large vessel vasculitis imaging · EULAR/PReS Still’s disease recommendations
6. Initial workup
TB testing and its limitations · Interpreting bacteriuria in the clinical context
The 2024 Delphi consensus describes a minimum evaluation for prolonged unexplained fever in an immunocompetent adult. Clinical clues can justify earlier targeted tests.
| Component | Proposed minimum and interpretation |
|---|---|
| Blood testing | CBC with differential; comprehensive metabolic panel including calcium and liver tests; ESR, CRP, ferritin, and TSH. Review trends and obtain a smear when counts suggest hematologic disease. |
| Microbiology | The consensus includes three blood-culture sets, urinalysis with microscopy, HIV Ag/Ab screening, and TB infection testing with an IGRA or TST. Adequate blood volume and collection before antibiotics when feasible are more important than waiting for a fever spike. Urine culture depends on the clinical context. A positive urine culture alone does not establish the fever source. IGRA and TST results cannot establish or exclude active TB. |
| Inflammatory serology | The consensus includes ANA, ANCA, and rheumatoid factor. Interpret in clinical context. Follow-up antibodies, complement, and organ-specific testing should be directed by the suspected syndrome. |
| Imaging | The consensus panel preferred CT chest, abdomen, and pelvis when available, including when a focal clue is absent. Chest radiography plus abdominal ultrasound is an alternative. The question being investigated and patient factors guide contrast use. |
| Additional tests | Hepatitis tests, EBV/CMV tests, fungal antigens, zoonotic serology, echocardiography, spine MRI, and lumbar puncture require a relevant question. They are not all routine FUO screening. |
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025.
Additional testing
| Clinical clue | Useful next step |
|---|---|
| Murmur, valve/device, embolic findings, or persistent bacteremia | TTE and TEE according to endocarditis suspicion and TTE quality; a limited negative TTE is insufficient. |
| Focal back pain or neurologic signs | MRI of the involved spine; urgent evaluation if cord compression is possible. |
| Enlarging node, skin lesion, or imaging target | Biopsy with pathology and appropriate microbiology rather than another broad antibody panel. |
| Cytopenias, abnormal smear, or organomegaly | Smear review, directed hematologic testing, and possible marrow/tissue evaluation. |
| Meningitis/encephalitis syndrome | CSF studies when safe, with imaging and empiric treatment according to urgency. |
| Mononucleosis-like illness or hepatitis | Selected EBV, CMV, or hepatitis testing according to the syndrome. Isolated IgG is insufficient to attribute fever to an acute infection. |
Repeat testing can be informative after an inadequate or early specimen or when new findings change the differential.
Focal findings can guide imaging before additional broad testing. Echocardiography evaluates suspected endocarditis, and MRI is the preferred test for suspected spinal infection. An accessible lesion may provide a biopsy target.
FDG PET/CT can help early in the evaluation of established FUO when the minimum workup is unrevealing, especially without a localizing clue. It may identify a biopsy target. Uptake occurs with infection, inflammation, and malignancy.
The 2024 EANM review found PET/CT diagnostically helpful in about 50% to 60% of patients. The studies were mostly observational and used different definitions of diagnostic yield. A negative scan may support observation in a stable patient but does not exclude all causes of fever.
Glucocorticoids can reduce inflammatory PET signal. In a stable patient, this affects scan timing. Urgent treatment takes precedence over scan yield.
Sources Hess et al. EANM consensus on FDG PET/CT in FUO and IUO. 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025.
8. Management and follow-up
For a stable immunocompetent patient without a time-sensitive syndrome, hydration, nutrition, and symptom control can continue during evaluation. Antipyretics may improve comfort. A response to acetaminophen, an NSAID, or glucocorticoids is nonspecific.
Safe withdrawal of a suspected drug can help assess drug fever. If it treats a confirmed infection, the plan accounts for continued effective therapy when needed.
A discharge plan includes a follow-up interval matched to the patient’s condition and clear ownership of pending results. Reassessment considers new symptoms, examination findings, blood counts, and renal or liver abnormalities.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · Someko et al. Drug fever. Annals of Clinical Epidemiology 2023.
9. Cases
For each case, discuss the differential, next test, and whether treatment should begin before results are available.
Case 1. A 68-year-old has five weeks of documented fever, elevated CRP, fatigue, and negative cultures. CT chest/abdomen/pelvis is unrevealing. On repeat questioning, there is new jaw fatigue with chewing and transient monocular dimming. What changes now?
Discussion
Jaw symptoms and transient monocular dimming raise concern for giant cell arteritis with threatened vision. Same-day specialist assessment and glucocorticoids are time-sensitive. Temporal and axillary ultrasound where expertise is available, or temporal artery biopsy, can support the diagnosis without delaying treatment.
Case 2. A stable patient with a prosthetic valve has four weeks of fever and recent amoxicillin exposure. Blood cultures are negative and a limited TTE shows no vegetation. How do the negative cultures and limited TTE affect the likelihood of endocarditis?
Discussion
A prosthetic valve and prior antibiotics raise concern for culture-negative endocarditis despite the limited TTE. Culture quality and antibiotic timing guide additional cultures, with TEE and endocarditis consultation informing the next decision. Persistently negative cultures can warrant Coxiella and Bartonella serology and other exposure-directed tests.
Case 3. A 45-year-old has four weeks of confirmed fever. Baseline evaluation and PET/CT are unrevealing. Counts, renal function, and liver tests are stable, there is no focal syndrome, and the patient is eating and ambulatory. Is a two-week broad-spectrum antibiotic course the next step?
Discussion
This stable patient has no finding that supports a broad-spectrum antibiotic trial. Medication review, symptom control, and follow-up are appropriate while the diagnosis remains uncertain. New focal symptoms or worsening laboratory findings warrant further evaluation.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · Dejaco et al. EULAR imaging recommendations for large vessel vasculitis, 2023 update. Published 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025. · Hess et al. EANM consensus on FDG PET/CT in FUO and IUO. 2024.
10. Presenting the assessment
Present the fever timeline, immune status, relevant exposures, examination findings, and abnormal tests. State the leading diagnoses and the reason for the next test.
Explain how the result would affect treatment or further testing.
Include the follow-up plan if testing remains negative.
Advanced fellow section
Additional evaluation when the initial workup is unrevealing.
FUO definitions and study limitations
The traditional temperature threshold is 38.3°C. The 2024 panel discussed lowering it to 38.0°C without reaching consensus. The panel emphasized a completed baseline evaluation, immune status, and geography. The panel considers FDG PET/CT an important early diagnostic test when available after the patient meets FUO criteria and the minimum workup is complete, particularly without a diagnostic clue. The scan is outside the diagnostic definition of FUO or IUO.
FUO studies differ in entry criteria, immune exclusions, referral populations, and prior testing. These differences limit comparisons of diagnostic yield.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024.
Culture-negative endocarditis
Prior antibiotics are a common cause of negative cultures in endocarditis. Antibiotic timing and culture quality guide further cultures, cardiac imaging, and discussion with microbiology when suspicion persists.
The 2025 AHA statement describes broadening microbiologic testing when cultures in suspected endocarditis remain negative at 72 hours. Options include Coxiella and Bartonella serology, Brucella testing if epidemiologically indicated, and selected molecular tests. The timing of echocardiography and treatment depends on clinical urgency. When surgery is planned, coordination with pathology and microbiology helps preserve valve material for complementary tests. Malignancy and autoimmune disease can cause sterile vegetations. Negative cultures alone are insufficient to establish nonbacterial thrombotic endocarditis.
Biopsy selection and specimen collection
| Target | Question and specimen planning |
|---|---|
| Enlarging or metabolically active node | Lymphoma, infection, granulomatous disease. Discuss core versus excisional sampling to preserve architecture; coordinate flow cytometry and cultures. |
| Persistent cytopenias or abnormal smear | Marrow disease, lymphoma, or disseminated infection may justify marrow examination. A normal peripheral count and no other clue weaken the case for blind marrow biopsy. |
| Skin lesion or ulcer | Biopsy a representative active lesion; obtain histology and tissue cultures when infection is possible. Superficial swab growth may represent colonization. |
| Granulomatous pathology | Correlate with exposures and immune state; nonnecrotizing granulomas are not specific for sarcoidosis. Negative stains alone do not exclude fungal or mycobacterial infection. |
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025. · ATS guideline on diagnosis and detection of sarcoidosis. 2020.
Molecular testing
Evidence for broad molecular testing in unselected FUO is limited. In selected cases with a strong infectious concern, such as unresolved blood culture-negative endocarditis, plasma microbial cell-free DNA or broad sequencing may supplement conventional testing. Contamination or incidental detection can yield a positive result. A negative result cannot exclude localized or low-burden infection.
Material from the involved site, when available, can support complementary molecular testing, conventional cultures, and pathology.
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · DeSimone et al. AHA scientific statement on blood culture-negative endocarditis. J Am Heart Assoc. 2025.
Recurrent fever and inflammatory disorders
| Pattern | Focused consideration | Limits |
|---|---|---|
| Discrete attacks with well intervals and serositis | Autoinflammatory disease, including familial Mediterranean fever; characterize onset, family history, and episode duration | Genetic testing is directed by phenotype and specialist assessment, not ethnicity alone. |
| Later-life inflammatory disease, macrocytic anemia, chondritis, skin disease, thrombosis | Consider VEXAS and discuss somatic UBA1 testing with hematology/rheumatology | An uncommon diagnosis requiring a compatible phenotype; not routine FUO screening. |
| Spiking fever, inflammatory arthritis, transient rash, neutrophilia | Still's disease after evaluation for infection and malignancy | Ferritin is supportive but nonspecific. The 2024 EULAR/PReS recommendations favor early IL-1 or IL-6 inhibition in established Still’s disease with the aim of limiting glucocorticoid exposure. |
| Fever, falling counts, hepatitis, coagulopathy, rising ferritin | HLH/MAS | Infection may trigger HLH and can remain active during the inflammatory illness. |
Sources Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. · Beck et al. Somatic UBA1 mutations and adult-onset autoinflammatory disease. NEJM 2020. · Fautrel et al. EULAR/PReS recommendations for Still's disease. 2024. · Shakoory et al. EULAR/ACR points to consider in suspected HLH/MAS. Published 2023.
PET/CT
An early FDG PET/CT after the minimum evaluation may identify an occult focus or biopsy site in a patient who meets FUO criteria. Specific findings may justify MRI, echocardiography, or direct biopsy earlier. FDG uptake occurs with infection, sterile inflammation, malignancy, and normal physiologic activity.
A negative PET/CT can support observation in a stable patient, with follow-up guided by symptoms and laboratory findings. Infection and malignancy remain possible. Glucocorticoids can reduce inflammatory uptake, so their timing affects interpretation. Vision-threatening vasculitis requires urgent treatment even when imaging is pending.
Sources EANM PET/CT consensus, 2024
Interpreting conflicting results
| Finding | Interpretation and next action |
|---|---|
| Positive low-level zoonotic antibody without a matching syndrome | Check assay, prior exposure, cross-reactivity, and timing. A single result may require paired titers or confirmation. |
| Positive Histoplasma and Blastomyces antigens | Cross-reactivity can produce both. Correlate with geography and tissue/culture; do not assume dual infection. |
| Negative early tickborne or zoonotic serology | Antibodies may not yet be detectable. Use organism-specific PCR when suitable, and repeat serology at the appropriate interval. |
| Ferritin elevation with inflammation | Does not distinguish infection, Still’s disease, malignancy, and HLH/MAS by itself. Falling counts and organ injury demand reassessment. |
| Granulomas with negative organism stains | Review sampling, cultures, molecular testing, host, and exposure. Do not equate nonnecrotizing granulomas with sarcoidosis. |
Sources CDC Q fever testing · CDC ehrlichiosis testing · CDC histoplasmosis testing · EULAR/ACR HLH/MAS points to consider
Follow-up after a negative workup
Follow-up includes reviewing the workup, medications, pending tests, and interval changes in symptoms or laboratory results. Progressive cytopenias, organ injury, or new focal symptoms require reassessment.
Improvement with an NSAID or glucocorticoid is nonspecific. If the suspected diagnosis warrants treatment, specimens obtained beforehand when feasible can improve diagnostic yield. The plan includes when to reassess the working diagnosis and treatment.
References
Wright et al. FUO and IUO modified Delphi consensus. OFID 2024. Table 5, final recommendations and minimum evaluation.
Hess et al. EANM consensus on FDG PET/CT in FUO and IUO. 2024.
Surviving Sepsis Campaign adult guidelines. 2026.
IDSA febrile neutropenia guideline. 2010 update, published 2011.
WHO meningitis guidelines. 2025.
SCCM/IDSA guideline on new fever in adult ICU patients. 2023.
Shakoory et al. EULAR/ACR points to consider in suspected HLH/MAS. Published 2023.
Someko et al. Drug fever. Annals of Clinical Epidemiology 2023.
Fautrel et al. EULAR/PReS recommendations for Still's disease. 2024.
ATS guideline on diagnosis and detection of sarcoidosis. 2020.
Beck et al. Somatic UBA1 mutations and adult-onset autoinflammatory disease. NEJM 2020.
Sources CDC Q fever testing · CDC brucellosis overview · CDC ehrlichiosis testing · CDC tularemia testing · CDC leptospirosis overview · CDC histoplasmosis testing · CDC Bartonella quintana overview · CDC malaria diagnosis · CDC HIV testing guidance